USE OF LIPOSOMES IN A CARRIER COMPRISING A CONTINUOUS HYDROPHOBIC PHASE FOR DELIVERY OF POLYNUCLEOTIDES IN VIVO

• US 20100203116A1
• Filed: 09/24/2008
• Published: 08/12/2010
• Est. Priority Date: 09/27/2007
• Status: Active Grant

• Current Assignee: HIMV LLC
• Original Assignee: Immunovaccine Technologies, Inc.
• Inventors: Karkada, Mohan, Mansour, Marc, Weir, Genevieve Mary
• Granted Patent: US 9,498,493 B2
• Time in Patent Office: Days
• US Class Current: 424/450
• CPC Class Codes: A61K 2039/55566 Emulsions, e.g. Freund's adjuvant, MF59
• CPC Class Codes: A61K 31/7088 Compounds having three or more nucleosides or nucleotides
• CPC Class Codes: A61K 38/208 IL-12
• CPC Class Codes: A61K 39/39 characterised by the immunostimulating additives, e.g. chemical adjuvants
• CPC Class Codes: A61K 48/0008 characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
• CPC Class Codes: A61K 9/107 Emulsions ; Emulsion preconcentrates; Micelles composition of emulsions A61K47/00
• CPC Class Codes: A61K 9/127 Liposomes
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 31/00 Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 37/02 Immunomodulators
• CPC Class Codes: A61P 37/08 Antiallergic agents antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 9/10 for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• CPC Class Codes: C12N 15/1136 against growth factors, growth regulators, cytokines, lymphokines or hormones
• CPC Class Codes: C12N 15/88 using microencapsulation, e.g. using amphiphile liposome vesicle
• CPC Class Codes: C12N 2310/14 interfering N.A.
• CPC Class Codes: C12N 2320/32 Special delivery means, e.g. tissue-specific

Abstract

The invention provides compositions comprising a carrier comprising a continuous phase of a hydrophobic substance, liposomes, and a polynucleotide, and methods for using such compositions for delivering a polynucleotide to a subject.

Claims

1. A composition comprising:

a carrier comprising a continuous phase of a hydrophobic substance;

liposomes; and

a polynucleotide.

2. The composition according to claim 1, wherein the carrier is an oil or a water-in-oil emulsion.

3. The composition according to claim 2, wherein the oil is a natural oil or a synthetic oil.

4. The composition according to claim 3, wherein the oil is mineral oil, a vegetable oil or a nut oil.

5. The composition according to claim 1, wherein the carrier comprises a mixture of oils.

6. The composition according to claim 1, wherein the liposomes comprise a phospholipid.

7. The composition according to claim 1, wherein the liposomes comprise cholesterol.

8. The composition of claim 1, wherein the liposomes comprise dioleoyl phosphatidylcholine (DOPC) and cholesterol.

9. The composition according to claim 1, wherein the polynucleotide encodes an antisense RNA, an interfering RNA, a catalytic RNA, a ribozyme, or a polypeptide.

10. The composition according to claim 1, further comprising an adjuvant.

11. The composition according to claim 1, wherein the polynucleotide is operably linked to a promoter functional in mammalian cells.

12. The composition according to claim 1, wherein said polynucleotide is inserted in an expression plasmid.

13. The composition according to claim 1, comprising a bacterial or viral vector containing said polynucleotide.

14. The composition according to claim 1, wherein said polynucleotide is present:

(a) encapsulated within said liposomes;

(b) exterior to said liposomes;

or

(c) both encapsulated within said liposomes and exterior to said liposomes.

15. The composition according to claim 10, wherein said adjuvant is present:

(a) within said liposomes;

(b) exterior to said liposomes;

or

(c) both within said liposomes and exterior to said liposomes.

16. A kit, comprising:

a composition of any one of claims 1 to 15;

and instructions for using said composition to deliver a polynucleotide to a subject.

17. A method for delivering a polynucleotide to a subject, comprising administering the composition of any one of claims 1 to 15 to said subject.

18. The method according to claim 17, wherein said subject is a mammal.

19. The method according to claim 17, wherein said mammal is a human.

23. The method according to any one of claims 20 to 22, wherein said polynucleotide is a polynucleotide as defined in any of the preceding claims.

20. A method for making a composition comprising combining liposomes, a polynucleotide, and a carrier comprising a continuous phase of a hydrophobic substance.

21. The method according to claim 20, wherein said polynucleotide is encapsulated in said liposomes.

22. The method according to claim 20 or 21, wherein the liposomes are dehydrated before they are combined with said carrier.

26. A composition produced by the method according to any one of claim 20.

24. (canceled)

25. (canceled)